203519-16-8 Usage
Uses
Used in Pharmaceutical Industry:
1-(4-Chlorophenylsulfonyl)hoMopiperazine, 95% is used as a key intermediate for the synthesis of various pharmaceuticals. Its application is primarily due to its ability to facilitate the creation of a wide range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(4-Chlorophenylsulfonyl)hoMopiperazine, 95% is utilized as an intermediate in the production of different agrochemicals. Its use is attributed to its role in synthesizing a variety of compounds that can be applied in agriculture to enhance crop protection and productivity.
Check Digit Verification of cas no
The CAS Registry Mumber 203519-16-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,5,1 and 9 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 203519-16:
(8*2)+(7*0)+(6*3)+(5*5)+(4*1)+(3*9)+(2*1)+(1*6)=98
98 % 10 = 8
So 203519-16-8 is a valid CAS Registry Number.
203519-16-8Relevant articles and documents
N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE
-
Page/Page column 50, (2010/02/14)
The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer’s Disease. Compounds of particular interest are defined by Formula (I), wherein R4, R5, R6, Rs
Substituted pyrimidine derivatives and their pharmaceutical use
-
, (2008/06/13)
PCT No. PCT/GB97/02029 Sec. 371 Date Feb. 12, 1999 Sec. 102(e) Date Feb. 12, 1999 PCT Filed Jul. 25, 1997 PCT Pub. No. WO98/06705 PCT Pub. Date Feb. 19, 1998This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.
